EZH2 and neoplasm: In 2021, Yu et al. reported a series of EZH2-targeting PROTACs, including E7, which mediated a decrease of PRC2 subunits and demonstrated superior inhibition of tumor growth compared to SMIs in DLBCL cells, irrespective of EZH2 mutation status.